Objective: To determine if intracranial pressure monitor placement in patients with acute liver failure is associated with significant clinical outcomes.
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May 2014 • Volume 42 • Number 5 monitoring in patients with acute liver failure, patient selection and ancillary assessments of cerebral blood flow likely have a significant role. Prospective studies would be required to conclusively account for confounding by illness severity and transplant. (Crit Care Med 2014; 42:1157-1167) Key Words: acetaminophen; acute liver failure; cerebral edema; fulminant hepatic failure; intracranial hypertension; intracranial pressure monitoring A cute liver failure (ALF) is defined by hepatic encephalopathy (HE) and synthetic dysfunction within 26 weeks of the first symptoms of liver disease (1) . Severe coagulopathy, HE, and hemodynamic instability contribute to a picture of multiple organ failure. Currently, the most common cause of ALF in North America is acetaminophen (APAP) (2, 3) . Particularly in APAP-induced ALF, cerebral edema and intracranial hypertension (ICH) are major causes of morbidity and mortality (4, 5) . Currently, the role of intracranial pressure (ICP) monitoring is still an area of controversy (6) .
ICP monitoring (ICPM) has generally been used primarily to exclude patients from liver transplant (LT) and to manage ICH intraoperatively when transplantation is performed. The presence of clinically significant ICH prior to emergency LT portends a higher likelihood of ischemic brain injury post LT (7, 8) . Furthermore, increased use of ICP-related interventions (including osmotic agents, propofol, and hyperventilation) are associated with ICPM (9) . This likely reflects an increase in detection of clinically silent ICH (10) . However, despite this rationale, a mortality benefit in ICPM ALF patients has not been previously demonstrated and no prospective controlled trials exist (9) .
The major concern previously with placement of such monitors is intracranial hemorrhage. An initial survey across medical centers in the United States described a complication rate of roughly 10% (27 of 263) with significantly higher rates in subdural or parenchymal compared with epidural transducers (11) . More recent studies from the United States (2005) and the United Kingdom (2010) have published rates of intracranial hemorrhage between 2.5% and 10% (9, 12) .
The U.S. Acute Liver Failure Study Group (ALFSG) has collected clinical and laboratory data on more than 2,300 patients with ALF over the past 15 years. In this study, we reviewed all ALF patients (n = 140) with grade III or IV HE who received an ICPM between March 2004 and August 2011. For control purposes, we examined all patients with ALF (n = 489) during the same time period with grade III or IV HE that did not receive an ICPM. We hypothesized that patients with ALF who underwent ICPM insertion would have significantly more manipulations to treat ICP and that this would beneficially impact 21-day survival. We also hypothesized that more patients undergoing LT would have ICPM and the rate of complications with ICPM insertion would be low.
Accordingly our objectives were as follows:
1. To determine whether placement of an ICPM in patients with ALF is significantly associated with 21-day mortality.
2. To determine the association between ICPM and management, specifically need for ICP therapies and listing/receipt of LT. 3. To determine the current safety profile of ICPM.
MATERIALS AND METHODS
The reporting of this study followed the Strengthening the Reporting of Observational Studies in Epidemiology guideline (13) .
Design and Setting
We performed a retrospective cohort study of a total of 629 patients with ALF (all patients with grade III or IV HE) enrolled by the U.S. ALFSG registry between March 2004 and August 2011. All enrolling centers are tertiary academic LT centers. The institutional review board at each participating center approved all protocols. One hundred forty (22%) received ICPM and 489 did not (controls). Because of HE in all patients, next of kin were asked to provide consent for study participation. Each center implemented monitoring and therapeutic interventions according to institutional standards of care. Although there were no study-wide protocols for indications for ICPM insertion or management of ICP across the U.S. ALFSG sites, based on previously published U.S. and U.K. literature, some indications for ICPM insertion may include hyperammonemia (ammonia > 150 μmol/L), listing for LT, meeting King's College criteria, or presence of multisystem organ failure (14, 15) .
Participants
Inclusion criteria were 1) evidence of ALF according to the enrollment criteria for the ALFSG (see Operational Definitions section), 2) age 18 years old or older, and 3) grade III or IV HE during the first 7 days of study admission (West Haven Criteria) (16, 17) .
Exclusion criteria were 1) cirrhosis/acute-on-chronic liver failure and 2) patients less than 18 years.
Operational Definitions
For the purposes of this study, ALF is defined as international normalized ratio (INR) more than or equal to 1.5 and HE within the first 26 weeks of liver disease in a patient with an acute hepatic insult (18) . HE grade is defined by the West Haven Criteria (simplified) as follows: grade 1, any alteration in mentation; grade 2, being somnolent or obtunded but easily rousable or presence of asterixis; grade 3, being rousable with difficulty, and grade 4, unresponsive to deep pain (16, 17) .
Variables
The exposure of interest was placement of an ICPM in patients with ALF (both APAP and non-APAP). The primary outcome of interest was 21-day mortality. Secondary outcomes included differences in management for ICH (ICP-related therapies, hypertonic saline, mannitol, hypothermia, barbiturates, and sedation [propofol] ) and complications of ICPM insertion. Confounding factors, which may impact the primary outcome (mortality), included age, gender, etiology of ALF (APAP vs non-APAP), requirement for organ support (vasopressors and mechanical ventilation [MV]), renal replacement therapy (RRT), and LT. Confounding factors that may affect the secondary outcome (complications of ICPM insertion) included type of ICPM and blood products used for placement.
Data Sources and Collection
Data were collected prospectively as part of the U.S. ALFSG and retrospectively analyzed. Prior to February 2010, each individual site prospectively sent case report forms to the University of Texas Southwestern for entry into a central database. Following this date, individual sites entered data electronically into a central database housed at the ALFSG Data Coordinating Center at the Medical University of South Carolina (Charleston, SC). Registry data assessed in this study included demographics (age, race, and sex), etiology of ALF, biochemistry (admission, day of ICPM insertion, or development of grade III or IV HE), requirement for organ support on day of admission or during first 7 days, ICP measurement (mm Hg), and requirement for ICP-related therapies and outcomes (receipt of LT and 21-day mortality). Data regarding the use of surrogate markers of ICP (reverse jugular bulb saturations and cerebral blood flow velocity) were not collected in the registry forms. Where available, the type of ICP transducer used (epidural, subdural, intraparenchymal, intraventricular, and lumbar) and hemostatic preparation used for ICPM placement (fresh-frozen plasma, cryoprecipitate, and recombinant factor VIIa) were examined. To acquire missing data (not initially captured) from U.S. ALFSG sites on ICPM techniques and complications, data queries were sent and source documentation was reviewed for missing data at all active recruiting sites of the U.S. ALFSG (n = 13/28).
Statistical Analysis
Statistical analysis was performed using IBM SPSS version 19 (SPSS, Chicago, IL) and SAS version 9.2 (SAS Institute, Cary, NC). In the event of missing values, data were not replaced or estimated. Data were analyzed using descriptive statistics to characterize demographics and other clinical variables. Categorical variables were compared using the chi-square test or Fisher exact test (< five subjects). For continuous variables, normally distributed variables were reported as means with sd and compared by Student t test. Nonnormally distributed continuous data were reported as medians with interquartile ranges (IQR) and compared by Wilcoxon rank-sum test. Survival was defined as the dichotomous outcome, alive at 21 days (transplant and transplant free) after enrollment into the registry. Transplant and transplant free refer to whether patients received LT during the first 21 days of follow-up. A two-sided significance level of less than 0.05 was used for all comparisons.
Multivariable Analysis
In order to control for variables that may confound the effect of ICPM on 21-day mortality, a multivariable logistic regression analysis was performed. The prespecified prognostic variables included age at admission into the registry, study enrollment year, high enrolling site (> 6 vs ≤ 6 patients enrolled per year; 6 was the median for all sites), gender, race (white vs nonwhite), lactate (admission), Model for End-stage Liver Disease (MELD) score (admission), receipt of LT during 21 days after enrollment, and receipt during the 7 days post study admission of MV, vasopressors, RRT, and ICPM. Model performance was assessed using the c-statistic and the Hosmer-Lemeshow test for goodness of fit. Multivariate associations are reported as odds ratios (OR) with 95% confidence limits.
RESULTS

General Characteristics of 629 ALF Patients With
Grade III/IV Hepatic Coma ICPM was used in 140 ALF patients with grade III/IV HE (22%) included in this analysis. Demographic, biochemical, and therapeutic characteristics of ICPM patients (n = 140) and controls (n = 489) are shown in Table 1 . There were no significant differences in gender (71% female) and race (74% Caucasian) between groups. The most common etiology of ALF was APAP (ICPM 49%, controls 52%, p = 0.05). Overall, ICPM patients were significantly younger (35 yr vs 43 yr; p < 0.001). On study admission (Table 1) , hematological indicators were similar apart from median platelet count (ICPM 133 vs controls 122; p = 0.02). ICPM patients had significantly higher bilirubin (7.5 vs 6.5 mg/dL; p = 0.03) and lower phosphate levels (mg/dL) (2.7 vs 3.3, p < 0.001).
During the first seven study days, ICPM patients were more likely to be on RRT (52% vs 38%), MV (98% vs 82%), and vasopressors (55% vs 39%, p < 0.004 for all). More ICPM patients received ICH-directed therapies, including mannitol (56% vs 21%), hypertonic saline (14% vs 7%), barbiturates (25% vs 5%), and hypothermia (24% vs 10%) (p < 0.03 for all) (Fig. 1) . More ICPM patients also received fresh-frozen plasma (84% vs 61%) and platelets (43% vs 25%) than controls (p < 0.001 for both).
Outcomes in 629 ALF Patients With Grade III/IV HE
Complications and outcomes are shown in Table 2 . There were no significant differences in complications (seizures, arrhythmias, gastrointestinal bleeding, bacteremia, tracheal aspirate infection, abnormal chest radiograph, or computed tomography; p > 0.1 for all comparisons). ICPM use was strongly associated with listing for LT (79% vs 27%, p < 0.001) and receipt of LT (41% vs 18%, p < 0.001). Overall 21-day mortality was similar between ICPM patients and controls when all (33% and 38%, p = 0. 24) or only non-LT patients (46% vs 45%, p = 0.92) were considered. There were no differences in rates of ICPM use comparing APAP with non-APAP patients (21% vs 23%, p = 0.48).
Patient Characteristics of 244 ALF Patients Listed for LT
In comparing ICPM patients orthotopic liver transplant (OLT) (n = 110) with controls (n = 134) listed for OLT (Supplemental Table 1 , Supplemental Digital Content 1, http://links.lww.com/CCM/A799), there was a trend toward an increased association between listed controls and receipt of OLT (controls 65% vs ICPM 53%, p = 0.05). However, in patients listed for LT, there were no associations between ICPM and overall (controls 20% vs ICPM 29%; p = 0.10) or transplant-free mortality at 21 days (47% vs 46%, p = 0.88).
Patient Characteristics of 145 Transplanted ALF Patients With Grade III/IV Hepatic Coma
Clinical and biochemical information on 55 ICPM and 85 control patients who underwent LT are presented in Table 3 (date of transplant was unavailable for five subjects). The median time to LT was similar in both groups (~ 2 d). Apart from ICPM patients having a significantly lower median INR (2.1 vs 3.0, p = 0.003), there were no other significant hematological or biochemical differences within 24 hours of LT (p ≥ 0.05 for all). During the inpatient phase prior to LT (up to 7 d), ICPM patients who underwent LT received vasopressors (55% vs 22%), MV (100% vs 75%), and RRT (56% vs 34%, p < 0.01 for all) more frequently than controls. ICPM patients received more mannitol (22% vs 7%) and barbiturates (15% vs 2%, p < 0.03 for both) than controls undergoing LT.
Preparation and Complications of ICPM in 140 ICPM ALF Patients
Of ICPM patients (n = 140), 85% received devices within 24 hours of study admission. The median INR (IQR) on the day of ICPM insertion was 2.2 (1.6-2.9) and platelet count 121 (87-174). On day of ICPM insertion, fresh-frozen plasma was given to 74% of ICPM patients, 19% received platelets, 4% received factor VIIa, and 32% received packed RBCs. Of 75 patients with known ICPM device, 17 received epidural catheters, 20 subdural, 18 intraparenchymal, seven intraventricular, and 13 lumbar monitors (Fig. 2) . Of 87 patients in the ICPM group with available detailed information, 44 patients (51%) had evidence of ICH (ICP > 25 mm Hg) during study period and overall 21-day mortality was higher in patients with evidence of ICH (43% vs 23%, p = 0.05). Where data were available (n = 87), there were no differences in prevalence of ICH between APAP (57%) and non-APAP (44%) patients (p = 0.24). In 56 ICPM patients where complete complication data were available, four (7%) reported evidence of significant neurological hemorrhage: intracranial (n = 3) and spinal (n = 1). One patient survived and the other three died due to For subjects who did not receive LT within the first 21 days, the likelihood of death increased as admission MELD increased. In patients who underwent LT, transplant is more protective with increasing admission MELD. 
DISCUSSION
Summary of Key Results
In this retrospective study of 629 patients with high-grade (III/IV) HE, we found that clinically significant ICH is common (~ 51%). ICPM use was significantly associated with listing for and receipt of LT. Patients with ICPM received significantly more ICH-directed therapies. However, when adjusting for confounding variables reflecting severity of illness, ICPM use in APAP-ALF was not significantly associated with mortality, whereas in non-APAP-ALF patients, it was associated with significantly increased 21-day mortality. In ICPM patients where complication data were available, 5% (n = 3) died directly of hemorrhagic complications related to ICPM insertion.
Comparison With Previous Studies
Although retrospective, this is the largest multicenter study to assess the potential benefit of ICPM in ALF patients recruited from U.S. ALFSG sites. Given the heterogeneity of indications for ICPM insertion across sites, judging appropriateness of a potential candidate for an ICPM is important to ensure generalizability of results. Bernal et al (14) previously reported that patients who had the highest risk of clinically significant ICH had high serum ammonia levels, required RRT, were hemodynamically unstable (required vasopressors), and were younger. In this cohort, patients who underwent ICPM insertion were significantly younger, had higher serum ammonia levels at admission (nonsignificant trend, p = 0.07), and had an increased requirement for RRT during the first 7 days. Thus, the patients undergoing ICPM use were appropriately selected. Our study confirms results of prior studies and also expands on these data. In this study, ICPM use was not associated with an improvement in 21-day survival in APAP-ALF patients, similar to an earlier study from our group (1998) (1999) (2000) (2001) (2002) (2003) (2004) and other older studies (9, 10, 19) . In this cohort, ICPM use once again was associated with more ICP-related interventions, possibly related to recognition of ICH (9) . ICP readings were not available in the earlier study; thus, we were somewhat surprised at the high rate of ICH (ICP > 25 mm Hg), with 51% showing ICH in this cohort. Besides an absence of previous studies demonstrating a survival benefit, another significant barrier to routine ICPM use is concern about intracranial hemorrhage. In our earlier study, the overall rate of hemorrhage was similar (10.3% experienced bleeding complications), and half of these were incidental radiographic findings and not clinically significant (9) . In a more recent study of 117 ALF patients from King's College Hospital, intracranial hemorrhage developed in three patients (2.5%) after ICPM placement (12) . Current conventional variables (INR, prothrombin time, and fibrinogen) do not reliably estimate hemostatic potential and bleeding risk in ALF (20, 21) . Prophylactic factor VIIa use was low in this cohort (~ 4%), whereas fresh-frozen plasma was used commonly on the day of ICPM insertion (74%) (22, 23) . The indiscriminant use of fresh-frozen plasma in patients with ALF provides large fluid volumes that may exacerbate ICH, particularly in patients who are not on RRT. Stravitz et al (21) demonstrated that despite elevated INR, many patients with ALF appear to maintain normal hemostasis by thromboelastography. A number of procoagulant pathways are activated that result in an increase in clot strength with increasing severity of liver injury (21) . Our bleeding rate of 5-7% is similar to previous studies (9, 12) and lower than the reports from the 1990s (11) . Similar rates have been reported by Kamat et al (24) recently (2012) in the pediatric literature as well. Perhaps, thromboelastography will guide the use of blood products in the future to further minimize the risk of clinically significant hemorrhage.
After controlling for confounding on multivariable analysis, ICPM in non-APAP patients was associated with increased 21-day mortality. As a retrospective study, we cannot comment directly on causation, but this raises a few possibilities. First, although there is risk of complications with ICPM insertion, the low bleeding rates in this cohort suggest that ICPM insertion per se likely did not contribute to the increased mortality (similar to Vaquero et al [9] ). Given the fact that surrogates of cerebral blood flow (e.g., transcranial Doppler and jugular bulb saturations) were not routinely used across most centers that manage ALF, it is possible that despite increased use of therapies for ICPM patients, they may not necessarily be appropriate (e.g., hyperventilation for cerebral hyperemia and mannitol for ICH). More likely, despite attempting to control for confounding by severity of illness in multivariable analysis, it is possible that sicker patients were more likely to undergo ICPM insertion in a nonrandomized fashion and that there are other unknown confounding variables (see Study Limitations section). This likely explains in part why a greater proportion of ICPM patients were listed for LT. This is also evident in the traumatic brain injury literature where several studies have failed to show a mortality benefit for extraventricular drainage devices despite their widespread acceptance (25, 26) . Finally, hyperacute liver failure (i.e., APAP) patients typically present with rapid development of HE, multiple organ failure, and cerebral edema compared with other etiologies and may be more likely to benefit from neuroprotective strategies and ICPM (14, 18, 27) . In light of these issues, although our results cannot conclusively confirm or refute the utility of ICPM in ALF patients, patient selection and ancillary assessments of cerebral blood flow likely have a significant role.
Study Limitations
Our study has limitations that warrant consideration. First, it is a retrospective analysis of prospectively collected data, thereby potentially predisposed to selection bias and residual confounding. Individual centers vary in volume and make independent decisions about listing for LT, insertion of an ICPM, type of device, and what prophylactic blood products to give. Although common indications for ICPM insertion described in the methods are based on recommendations from data from King's College Hospital (14) and the U.S. ALFSG (15) , both of these studies were published after this cohort began. Despite several reviews of source data, we did not have complete ICP, monitor, and complication data. Patients were not assigned randomly to ICPM and given that listing for LT was associated with increased use of ICPM, it is possible that monitoring in LT candidates was undertaken in sicker patients, although epidemiological and clinical variables were similar at admission and prior to the procedure. A prospective randomized study with standardized ICP management protocols would address these issues of bias; however, no prospective studies have been performed to date. We attempted to control for confounding by performing multivariable analysis accounting for severity of liver dysfunction (MELD) and multiple organ failure (requirement for vasopressors, RRT, and MV). Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation (APACHE) II could not be accurately calculated due to lack of detailed information on vasopressor doses (SOFA) and Glasgow Coma Score (APACHE II; only hepatic coma grade available).
CONCLUSIONS
When ICPM is performed in ALF patients, ICH is commonly observed. The use of ICPM in APAP-ALF did not confer a significant 21-day mortality benefit, whereas in non-APAP-ALF, it may be associated with worse outcomes. Significant hemorrhagic complications from ICPM placement were uncommon and cannot account for trends in mortality. Although our results cannot conclusively confirm or refute the utility of ICPM in ALF patients, patient selection and ancillary assessments of cerebral blood flow likely have a significant role.
Prospective studies would be required to conclusively account for confounding by illness severity and transplant.
